CAS Number93106-60-6
Synonymsbayvp2674; Enorfloxacin; Enrolfoxacin; 1-cyclopropyl-7-(4-ethyl-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid; cfpq; Enrofoxacin; Enrofloxacin; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-quinoline-3-carboxylic acid; 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; ROFLOXACIN BASE; MFCD01861684; Baytri; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethylpiperazino)-quinoline-3-carboxylic acid
Molecular FormulaC19H22FN3O3
Molecular Weight359.39
Purity≥99.0%
Density1.4±0.1 g/cm3
Boiling Point560.5±50.0 °C at 760 mmHg
Melting Point225 °C
Appearancepowder or crystals
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 93106-60-6 |
| Catalog No. | 2A-9010334 |
| Chinese Name | 恩诺沙星 |
| Synonyms | bayvp2674; Enorfloxacin; Enrolfoxacin; 1-cyclopropyl-7-(4-ethyl-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid; cfpq; Enrofoxacin; Enrofloxacin; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-quinoline-3-carboxylic acid; 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; ROFLOXACIN BASE; MFCD01861684; Baytri; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethylpiperazino)-quinoline-3-carboxylic acid |
| Molecular Formula | C19H22FN3O3 |
| Molecular Weight | 359.39 |
| Purity | ≥99.0 |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 560.5±50.0 °C at 760 mmHg |
| Melting Point | 225 °C |
| Appearance | powder or crystals |
| Storage Condition | Closed, cool, dry place |
| Application | Enrofloxacin is an effective antibiotic against Mycoplasma bovis with a MIC90 of 0.312 μg/mL. |
| PubChem ID | 329751571 |
| MDL Number | MFCD00792463 |
| SMILES | CCN1CCN(CC1)c2cc3N(C=C(C(O)=O)C(=O)c3cc2F)C4CC4 |
| InChI | 1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26) |
| InChI Key | SPFYMRJSYKOXGV-UHFFFAOYSA-N |
| Beilstein/REAXYS | 5307824 |
| NACRES Code | NA.21 |
| UNSPSC | 41116105 |
| Hazard Symbols | Transport |
| MSDS | msds/10334_1_93106_60_6.pdf |
| Bioactivity | Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection Target MIC90: 0.312 μg/mL ( Mycoplasma bovis)[1] In Vitro Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1]. In Vivo Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2]. Animal Admin Mice[2] 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized[2]. References [1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. [2]. Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 560.5±50.0 °C at 760 mmHg Melting Point 225 °C Molecular Formula C19H22FN3O3 Molecular Weight 359.395 Flash Point 292.8±30.1 °C Exact Mass 359.164520 PSA 65.78000 LogP 1.88 Vapour Pressure 0.0±1.6 mmHg at 25°C Index of Refraction 1.634 InChIKey SPFYMRJSYKOXGV-UHFFFAOYSA-N SMILES CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1 Storage condition -20°C Freezer |
| Use of | Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Properties Articles131 Name enrofloxacin Synonym More Synonyms Enrofloxacin Biological Activity Description Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection MIC90: 0.312 μg/mL ( Mycoplasma bovis)[1] In Vitro Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1]. References [1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. [2]. Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54. Chemical & Physical Properties Molecular Formula C19H22FN3O3 Exact Mass 359.164520 PSA 65.78000 Index of Refraction 1.634 InChIKey SPFYMRJSYKOXGV-UHFFFAOYSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Ecenofloxacin | 162301-05-5 | 2A-9010274 |
| Efavirenz | 154598-52-4 | 2A-9010286 |
| Emtricitabine | 143491-57-0 | 2A-9010311 |
| Enalapril | 75847-73-3 | 2A-9010312 |
| Enalapril maleate | 76095-16-4 | 2A-9010313 |
| Epirubicin | 56420-45-2 | 2A-9010348 |
| Epirubicin hydrochloride | 56390-09-1 | 2A-9010349 |
| Epirubicinol | 2A-301433 | 2A-9010350 |
| Eprosartan | 133040-01-4 | 2A-9010355 |
| Erythromycin estolate | 3521-62-8 | 2A-9010372 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS